GLP-1受体激动剂治疗2型糖尿病合并脂肪肝患者的效果

摘要/Abstract

摘要： 目的探究LP-1受体激动剂对2型糖尿病合并脂肪肝患者血糖、血脂和体质量影响。方法将2016年1月—2018年12月间收治的110例2型糖尿病合并脂肪肝患者,依据数字表法随机分为观察组和对照组,每组55例。对照组采用常规降糖、调脂和抗炎治疗。观察组患者在此基础上加用GLP-1受体激动剂治疗。对比两组患者血糖、血脂、体质量和脂肪沉积影响。结果治疗后观察组患者血糖水平显著低于对照组(P<0.05)。治疗后观察组患者血脂水平显著低于对照组(P<0.05)。治疗观察组患者体质量指数和肝脏脂肪沉积率显著低于对照组(P<0.05)。结论 GLP-1受体激动剂对2型糖尿病合并脂肪肝患者的血糖和血脂水平具有良好调节效果,从而改善患者的体质量和脂肪沉积。

王倩, 李秀丽, 杨楠, 王秀萍, 段锦花. GLP-1受体激动剂治疗2型糖尿病合并脂肪肝患者的效果[J]. 肝脏, 2019, 24(9): 1060-1062.

参考文献

[1] Kirkman MS, Mahmud H, Korytkowski MT. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. Endocrinol Metab Clin North Am, 2018, 47:81-96.
[2] Dai W, Ye L, Liu A, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine, 2017, 96:e8179.
[3] Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action. Diabetes Care, 2017, 40:419-430.
[4] Holman RR, Bethel MA, Mentz RJ , et al. Effect of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2017, 377:1228.
[5] Wang Z, Hou L, Huang L , et al. Exenatide improves liver mitochondrial dysfunction and insulin resistance by reducing oxidative stress in high fat diet-induced obese mice. Biochem Biophys Res Commun., 2017, 486:116-123.
[6] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2013年版). 中国糖尿病杂志, 2014, 30:893-942.
[7] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 胃腸病學和肝病學雜誌, 2010, 19:167-170.
[8] 刘丽, 张宇. 利拉鲁肽注射液对2型糖尿病合并非酒精性脂肪肝患者肝脏脂肪沉积的影响. 肝脏, 2018, 23.
[9] Yoon JH, Min SH, Ahn CH , et al. Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis. Sci Rep, 2018, 8:4095.
[10] 陈雪阳, 徐明智. 胰高血糖素样肽1在糖尿病治疗中的相关研究及应用. 中华危重症医学杂志(电子版), 2017, 10:58.
[11] Zhou S, Zhang M, Zhu M. Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy. Mol Med Rep, 2014, 10:2351-2357.
[12] Bi Y, Zhang B, Xu W, et al. Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes. Acta Diabetologica, 2014, 51:865-873.
[13] Armstrong M J, Gaunt P, Aithal G P, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, 2016, 387:679-690.
[14] Shao N, Kuang H Y, Hao M, et al. Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. Diabetes Metab Res Rev, 2015, 30:521-529.
[15] Armstrong M, Houlihan D, Rowe I , et al. Safety and efficacy of liraglutide in patients with type 2 diabetes with elevated liver enzymes: individual patient data meta-analysis of the LEAD programme. Lancet, 2013, 381: S20.